Amylyx Appoints Dan Monahan As Chief Commercial Officer

Amylyx Pharmaceuticals, Inc. has announced the appointment of Dan Monahan as Chief Commercial Officer, adding him to the Company’s Leadership Team. Mr. Monahan, who joined Amylyx in January 2024, brings over 20 years of experience in commercial leadership within the biopharmaceutical industry. His specialising areas include sales, marketing, and market access across diverse product lines.

Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, said in a statement, “We are excited to announce the appointment of Dan Monahan to Chief Commercial Officer as Amylyx prepares for the first participant dosed in the Phase 3 LUCIDITY clinical trial of avexitide for the treatment of post-bariatric hypoglycemia planned in the first quarter of 2025. Dan has a strong track record of launching medicines and excels in building and leading high-performing teams that have brought new medicines to communities with high unmet needs.”

He further added,  “Since joining Amylyx earlier this year, Mr Monahan has demonstrated invaluable leadership as we work towards ensuring launch readiness for the avexitide program ahead of Phase 3 data expected in 2026 and potential future launches. We are confident that adding Mr Monahan to our leadership team will play a crucial role in delivering a meaningful impact to the PBH community as we continue to move forward with our goal of avexitide being the first therapy approved for people living with PBH.”

Throughout his career, Mr. Monahan has been dedicated to launching therapies that address significant unmet medical needs, ensuring patients access critical treatments. Before joining Amylyx, he served as Vice President and Head of CNS Marketing and Portfolio Strategy at Otsuka Pharmaceuticals. In this role, he led U.S. commercialisation for key CNS products, including REXULTI® and ABILIFY MAINTENA®, which have been instrumental in addressing severe mental health conditions. 

Dan Monahan, Chief Commercial Officer of Amylyx, commented, “I look forward to continuing to collaborate with the team on advancing novel therapies from development through commercialisation, with our first focus on avexitide for the potential treatment of post-bariatric hypoglycemia. Since joining Amylyx, I have seen first-hand both the resilience of those with post-bariatric hypoglycemia and the significant quality of life-impacts that this debilitating condition can have. I am deeply motivated by the opportunity to support people living with PBH and potentially address the critical unmet need for a treatment option.”

Before Otsuka, he held senior leadership positions at Novartis, overseeing the commercial success of COSENTYX®, a flagship dermatology brand for autoimmune conditions. Earlier in his career, Mr. Monahan spent 14 years at Sanofi, where he advanced through roles of increasing responsibility in sales, marketing, and market access. A United States Military Academy graduate at West Point, Mr. Monahan also served as a Field Artillery Officer in the U.S. Army. He later earned his MBA from Seton Hall University.

In his new role at Amylyx, Mr Monahan will lead commercialisation efforts, focusing on the potential approval of avexitide, the company’s investigational, first-in-class GLP-1 receptor antagonist for treating post-bariatric hypoglycemia (PBH). Amylyx is set to launch LUCIDITY, a Phase 3 clinical trial to evaluate avexitide’s efficacy and safety in PBH patients, in the first quarter of 2025.